DaVita Inc. (DVA) Stock

DaVita Inc. specializes in providing essential kidney dialysis services to patients with chronic kidney failure. Operating a network of outpatient dialysis centers, the company offers comprehensive care that includes outpatient, hospital inpatient, and home-based hemodialysis services. DaVita also manages clinical laboratories, which conduct routine and specialized laboratory tests for end-stage renal disease (ESRD) patients, alongside providing vascular access services and physician care. Additionally, the company delivers disease management programs to over 16,000 patients under risk-based integrated care arrangements and serves another 7,000 patients through various integrated care models.

In the United States, DaVita operates 2,815 outpatient dialysis centers, supporting approximately 203,100 patients as of December 31, 2021. Beyond its domestic footprint, the company extends its services globally with 339 outpatient dialysis centers across 10 countries, catering to approximately 39,900 patients. DaVita further enhances its healthcare offerings through acute inpatient dialysis services in about 850 hospitals nationwide, complemented by comprehensive laboratory services. This extensive network underscores DaVita's commitment to delivering high-quality kidney care and enhancing patient outcomes.

Founded in 1994 and headquartered in Denver, Colorado, DaVita Inc. has evolved as a leader in the dialysis and kidney care sector, focusing on patient-centered services and clinical excellence. Formerly known as DaVita HealthCare Partners Inc., the company rebranded to DaVita Inc. in 2016, reflecting its dedication to advancing healthcare delivery and expanding access to critical kidney treatment services.